Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Tremonton
Archived
•
November 10, 2026
•
LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depressionApproximately 120 participants planned for the study, which incorporates insights from the previous Phase 3 trial to promote site and data qualityTopline results from…
Source: The Leader (Tremonton) | https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



